Patents by Inventor Jayaraman Kannapan
Jayaraman Kannapan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11447513Abstract: The present application provides processes for the purification of ferric carboxymaltose, the process includes the steps of dissolving crude ferric carboxymaltose in a first solvent; charging the ferric carboxymaltose solution in a reaction vessel with a second solvent and precipitating therefrom a ferric carboxymaltose precipitate; and isolating pure ferric carboxymaltose from the ferric carboxymaltose precipitate.Type: GrantFiled: February 11, 2021Date of Patent: September 20, 2022Assignee: RK PHARMA INC.Inventors: Ravishanker Kovi, Jayaraman Kannapan, Hemant Mande, Rajesh Patel, Ritesh H Panchal, Varun L Zambare
-
Publication number: 20210277041Abstract: The present application provides processes for the purification of ferric carboxymaltose, the process includes the steps of dissolving crude ferric carboxymaltose in a first solvent; charging the ferric carboxymaltose solution in a reaction vessel with a second solvent and precipitating therefrom a ferric carboxymaltose precipitate; and isolating pure ferric carboxymaltose from the ferric carboxymaltose precipitate.Type: ApplicationFiled: February 11, 2021Publication date: September 9, 2021Inventors: Ravishanker Kovi, Jayaraman Kannapan, Hemant Mande, Rajesh Patel, Ritesh H Panchal, Varun L Zambare
-
Patent number: 11034714Abstract: Novel processes for making the N-pyrrazole substituted 2-adenosine derivative regadenoson and a novel polymorph thereof. The novel polymorph of regadenoson designated form H and drug substances and pharmaceutical compositions including the novel polymorph H are disclosed.Type: GrantFiled: August 28, 2019Date of Patent: June 15, 2021Inventors: Ravishanker Kovi, Jayaraman Kannapan, Piyush D. Fadadu, Ashish Naik
-
Publication number: 20200316097Abstract: The present application provides a stable, ready-to-use fosaprepitant dimeglumine formulation which is easy to administer without need of any reconstitution step and has a desirable solubility, stability and safety profile. The concentration of the fosaprepitant dimeglumine in the liquid formulation is preferably less than about 80 mg/ml, or more preferably between about 20 mg/ml to about 60 mg/ml. In certain embodiments, the liquid formulation retains at least about 90% chemical stability of the fosaprepitant dimeglumine after storage for a commercially reasonable amount of time at a temperature between about 0° C. to about 40° C.Type: ApplicationFiled: February 28, 2020Publication date: October 8, 2020Inventors: Ravishanker Kovi, George Roby Thomas, Jayaraman Kannapan, Nirmal Chaitanya Indravadanbhai, Patel Mitesh Manubhai, Thupalli Ajeykumar Reddy, Vamshi Yekkanti
-
Publication number: 20200017539Abstract: Novel processes for making the N-pyrrazole substituted 2-adenosine derivative regadenoson and a novel polymorph thereof. The novel polymorph of regadenoson designated form H and drug substances and pharmaceutical compositions including the novel polymorph H are disclosed.Type: ApplicationFiled: August 28, 2019Publication date: January 16, 2020Inventors: Ravishanker Kovi, Jayaraman Kannapan, Piyush D. Fadadu, Ashish Naik
-
Patent number: 10442813Abstract: Novel polymorphs of rucaparib camsylate include Form alpha having XRPD peaks at diffraction angles (2?) of 6.14±0.2, 12.41±0.2, 15.34±0.2, 15.95±0.2, 16.36±0.2, 16.51±0.2 and 19.67±0.2, Form beta having XRPD peaks at diffraction angles (2?) of 6.86±0.2, 9.58±0.2, 12.75±0.2, 14.56±0.2, 15.05±0.2, 20.76±0.2 and 22.45±0.2, and Form gamma having XRPD peaks at diffraction angles (2?) of 9.5±0.2, 12.73±0.2, 14.77±0.2, 15.16±0.2, 20.62±0.2, 22.33±0.2, 22.63±0.2 and 27.29±0.2. Methods are disclosed for the preparation of such polymorphic forms and pharmaceutical compositions containing such polymorphic forms. A method is disclosed for preparing a highly pure Form B of rucaparib camsylate. Pharmaceutical compositions containing highly pure Form B prepared by the method are disclosed.Type: GrantFiled: January 29, 2019Date of Patent: October 15, 2019Assignee: RK PHARMA SOLUTIONS LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Ananda Babu Thirunavakarasu, Hemant Mande
-
Patent number: 10442832Abstract: Novel processes for making the N-pyrrazole substituted 2-adenosine derivative regadenoson and a novel polymorph thereof. The novel polymorph of regadenoson designated form H and drug substances and pharmaceutical compositions including the novel polymorph H are disclosed.Type: GrantFiled: February 2, 2016Date of Patent: October 15, 2019Assignee: APICORE US LLCInventors: Ravishanker Kovi, Ashish Naik, Piyush Fadadu, Jayaraman Kannapan
-
Patent number: 10392417Abstract: Processes are provided for the preparation of a stable polymorphic form C of regadenoson, the process involving steps of a) obtaining a solution of regadenoson in benzyl alcohol solvent, b) maintaining the reaction mixture of step a) to about 10° C. to about 90° C., and c) isolating the stable polymorphic form C of regadenoson. Polymorphic form C may be characterized by an x-ray powder diffraction pattern with peaks at about 6.1, 10.2, 10.6, 19.0 and 25.4.±0.2 degrees 2-theta.Type: GrantFiled: October 30, 2017Date of Patent: August 27, 2019Assignee: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Ananda Babu Thirunavakarasu, Piyush D. Fadadu, Piyush B. Thumar
-
Publication number: 20190233428Abstract: Novel polymorphs of rucaparib camsylate include Form alpha having XRPD peaks at diffraction angles (2?) of 6.14±0.2, 12.41±0.2, 15.34±0.2, 15.95±0.2, 16.36±0.2, 16.51±0.2 and 19.67±0.2, Form beta having XRPD peaks at diffraction angles (2?) of 6.86±0.2, 9.58±0.2, 12.75±0.2, 14.56±0.2, 15.05±0.2, 20.76±0.2 and 22.45±0.2, and Form gamma having XRPD peaks at diffraction angles (2?) of 9.5±0.2, 12.73±0.2, 14.77±0.2, 15.16±0.2, 20.62±0.2, 22.33±0.2, 22.63±0.2 and 27.29±0.2. Methods are disclosed for the preparation of such polymorphic forms and pharmaceutical compositions containing such polymorphic forms. A method is disclosed for preparing a highly pure Form B of rucaparib camsylate. Pharmaceutical compositions containing highly pure Form B prepared by the method are disclosed.Type: ApplicationFiled: January 29, 2019Publication date: August 1, 2019Applicant: RK Pharma Solutions LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Ananda Babu Thirunavakarasu, Hemant Mande
-
Patent number: 10221184Abstract: Novel crystalline ponatinib hydrochloride forms designated Form alpha and Form beta are disclosed. Form alpha is characterized by data selected from an XRPD pattern with peaks at about 6.5, 9.0, 12.25, 14.4, 16.70, 19.6, 22.2, 24.5, 28.2±0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG. 1; and/or a combination thereof. Form beta is characterized by data selected from an XRPD pattern with peaks at about 10.7, 15.2, 15.8, 16.4 23.1, 25.0, 27.8±0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG. 3; and/or combinations thereof. Processes for making Form alpha and Form beta are disclosed.Type: GrantFiled: January 4, 2018Date of Patent: March 5, 2019Assignee: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Ananda Babu Thirunavakarasu, Gaurav Yadav, Veerabhadra Rao Bobbili, Shivnath Sahebrao Patil, Sanjay F. Thakor
-
Publication number: 20180208599Abstract: Novel crystalline ponatinib hydrochloride forms designated Form alpha and Form beta are disclosed. Form alpha is characterized by data selected from an XRPD pattern with peaks at about 6.5, 9.0, 12.25, 14.4, 16.70, 19.6, 22.2, 24.5, 28.2±0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG. 1; and/or a combination thereof. Form beta is characterized by data selected from an XRPD pattern with peaks at about 10.7,15.2, 15.8, 16.4 23.1, 25.0, 27.8±0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG. 3; and/or combinations thereof. Processes for making Form alpha and Form beta are disclosed.Type: ApplicationFiled: January 4, 2018Publication date: July 26, 2018Applicant: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Ananda Babu Thirunavakarasu, Gaurav Yadav, Veerabhadra Rao Bobbili, Shivnath Sahebrao Patil, Sanjay F. Thakor
-
Patent number: 9988389Abstract: Methods are disclosed for making 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide, intermediates and pharmaceutically acceptable salts thereof.Type: GrantFiled: June 10, 2016Date of Patent: June 5, 2018Assignee: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Sanjay F. Thakor, Ashish Naik, Dhakhada Chetana Bharatbhai, Khichi Kuldip Fatehlal, Shivnath Sahebrao Patil
-
Publication number: 20180127452Abstract: Processes are provided for the preparation of a stable polymorphic form C of regadenoson, the process involving steps of a) obtaining a solution of regadenoson in benzyl alcohol solvent, b) maintaining the reaction mixture of step a) to about 10° C. to about 90° C., and c) isolating the stable polymorphic form C of regadenoson. Polymorphic form C may be characterized by an x-ray powder diffraction pattern with peaks at about 6.1, 10.2, 10.6, 19.0 and 25.4.±0.2 degrees 2-theta.Type: ApplicationFiled: October 30, 2017Publication date: May 10, 2018Applicant: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Ananda Babu Thirunavakarasu, Piyush D. Fadadu, Piyush B. Thumar
-
Publication number: 20180044345Abstract: Methods are disclosed for making 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide, intermediates and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: October 17, 2017Publication date: February 15, 2018Inventors: Ravishanker Kovi, Jayaraman Kannapan, Sanjay F. Thakor, Ashish Naik, Dhakhada Chetana Bharatbhai, Khichi Kuldip Fatehlal, Shivnath Sahebrao Patil
-
Publication number: 20180037606Abstract: Racemization-free methods are disclosed for the synthesis of carfilzomib. Novel intermediates and methods of making carfilzomib employing fragment condensation using the novel intermediates are disclosed. Amorphous carfilzomib and methods of making same are disclosed.Type: ApplicationFiled: October 17, 2017Publication date: February 8, 2018Applicant: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Vasanthakumar G. Ramu, Alaparthi Lakshmi Prasad, Talluri Bhushaiah Chowdary, Gaurav Kulkarni, Saiyed Akeel Ahmed Shakeel Ahmed, Veerabhadra Rao Bobbili, N V Raghavalu Dusanapudi, Anand V. Mantri
-
Publication number: 20180009825Abstract: Novel processes are disclosed for the preparation of eribulin mesylate. Novel intermediate compounds used in the processes for making eribulin mesylate as well as processes for making the intermediates are disclosed.Type: ApplicationFiled: July 5, 2017Publication date: January 11, 2018Applicant: Apicore US LLCInventors: Ravishanker Kovi, Sanjay Thakor, Ashish Naik, Jayaraman Kannapan
-
Patent number: 9822145Abstract: Racemization-free methods are disclosed for the synthesis of carfilzomib. Novel intermediates and methods of making carfilzomib employing fragment condensation using the novel intermediates are disclosed. Amorphous carfilzomib and methods of making same are disclosed.Type: GrantFiled: August 4, 2016Date of Patent: November 21, 2017Assignee: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Vasanthakumar G Ramu, Alaparthi Lakshmi Prasad, Talluri Bhushaiah Chowdary, Gaurav Kulkarni, Saiyed Akeel Ahmed Shakeel Ahmed, Veerabhadra Rao Bobbili, N V Raghavalu Dusanapudi, Anand V. Mantri
-
Publication number: 20170260157Abstract: Processes are disclosed for making pomalidomide which involve reducing 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione using a catalyst and at least one solvent. The process may include reacting 3-nitrophthalic anhydride with ?-amino glutarimide hydrochloride to obtain the 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione. The process may further include, prior to the reducing step, subjecting the 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione to a purification process comprising heating a mixture of 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione and 1,4-dioxane to obtain a solution, treating the obtained solution with carbon, removing the carbon from the solution to obtain a purified 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione solution and using the purified 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione solution for the reducing step.Type: ApplicationFiled: March 7, 2017Publication date: September 14, 2017Applicant: Apicore US LLCInventors: Ravishanker Kovi, Veerabhadra Rao Bobbili, Jayaraman Kannapan
-
Publication number: 20170008848Abstract: Methods are disclosed for the preparation of netupitant and pharmaceutically acceptable salts thereof which are novel, easily reproducible, environmentally safe and cost effective. The methods may employ inexpensive starting materials and the preparation processes for intermediates are simple and highly reproducible. Novel intermediates for the preparation of netupitant and pharmaceutically acceptable salts thereof are also disclosed. Amorphous netupitant and methods of making same are disclosed.Type: ApplicationFiled: September 23, 2016Publication date: January 12, 2017Inventors: Ravishanker Kovi, Jayaraman Kannapan, Sanjay F. Thakor, Ashish Naik
-
Publication number: 20160368875Abstract: Methods are disclosed for the preparation of netupitant and pharmaceutically acceptable salts thereof which are novel, easily reproducible, environmentally safe and cost effective. The methods may employ inexpensive starting materials and the preparation processes for intermediates are simple and highly reproducible. Novel intermediates for the preparation of netupitant and pharmaceutically acceptable salts thereof are also disclosed. Amorphous netupitant and methods of making same are disclosed.Type: ApplicationFiled: September 6, 2016Publication date: December 22, 2016Inventors: Ravishanker Kovi, Jayaraman Kannapan, Sanjay F. Thakor, Ashish Naik